PT3139925T - Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos - Google Patents

Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos

Info

Publication number
PT3139925T
PT3139925T PT157244385T PT15724438T PT3139925T PT 3139925 T PT3139925 T PT 3139925T PT 157244385 T PT157244385 T PT 157244385T PT 15724438 T PT15724438 T PT 15724438T PT 3139925 T PT3139925 T PT 3139925T
Authority
PT
Portugal
Prior art keywords
treatment
movement disorders
hyperkinetic movement
vmat2 inhibitors
vmat2
Prior art date
Application number
PT157244385T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of PT3139925T publication Critical patent/PT3139925T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT157244385T 2014-05-06 2015-05-06 Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos PT3139925T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06

Publications (1)

Publication Number Publication Date
PT3139925T true PT3139925T (pt) 2022-01-26

Family

ID=53264772

Family Applications (2)

Application Number Title Priority Date Filing Date
PT211788823T PT3936130T (pt) 2014-05-06 2015-05-06 Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos
PT157244385T PT3139925T (pt) 2014-05-06 2015-05-06 Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT211788823T PT3936130T (pt) 2014-05-06 2015-05-06 Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos

Country Status (24)

Country Link
US (3) US20170071932A1 (cg-RX-API-DMAC7.html)
EP (3) EP4389227A3 (cg-RX-API-DMAC7.html)
JP (4) JP6635945B2 (cg-RX-API-DMAC7.html)
KR (5) KR20220140647A (cg-RX-API-DMAC7.html)
CN (3) CN112741836A (cg-RX-API-DMAC7.html)
AU (1) AU2015256012B2 (cg-RX-API-DMAC7.html)
CA (1) CA2947736C (cg-RX-API-DMAC7.html)
CY (1) CY1125058T1 (cg-RX-API-DMAC7.html)
DK (2) DK3936130T3 (cg-RX-API-DMAC7.html)
ES (2) ES2976207T3 (cg-RX-API-DMAC7.html)
FI (1) FI3936130T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20240459T1 (cg-RX-API-DMAC7.html)
HU (2) HUE057839T2 (cg-RX-API-DMAC7.html)
IL (1) IL248745B (cg-RX-API-DMAC7.html)
LT (2) LT3139925T (cg-RX-API-DMAC7.html)
MX (1) MX387625B (cg-RX-API-DMAC7.html)
NZ (1) NZ725826A (cg-RX-API-DMAC7.html)
PL (2) PL3936130T3 (cg-RX-API-DMAC7.html)
PT (2) PT3936130T (cg-RX-API-DMAC7.html)
RS (2) RS65359B1 (cg-RX-API-DMAC7.html)
RU (1) RU2753740C2 (cg-RX-API-DMAC7.html)
SI (2) SI3936130T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202400199T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015171802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7109360B2 (ja) 2015-10-30 2022-07-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジン塩およびその多形体
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
CN109153676B (zh) * 2016-06-29 2021-08-10 苏州科睿思制药有限公司 Nbi-98854的晶型及其制备方法和用途
JP2020500875A (ja) * 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
EA201991782A1 (ru) 2017-01-27 2021-09-23 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2022104034A (ru) * 2017-04-01 2022-03-05 Адептио Фармасьютикалз Лимитед Фармацевтические композиции
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2771164C2 (ru) * 2017-04-01 2022-04-27 Адептио Фармасьютикалз Лимитед (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2019074492A1 (en) * 2017-10-10 2019-04-18 Obrien Christopher F METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
US11306082B2 (en) * 2017-11-08 2022-04-19 Foresee Pharmaceuticals Co., Ltd. Esters of dihydrotetrabenazine
WO2019129100A1 (zh) 2017-12-26 2019-07-04 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
US12144899B2 (en) * 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
IL320987A (en) 2018-08-15 2025-07-01 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
EP3965764A1 (en) * 2019-05-09 2022-03-16 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2081929E (pt) * 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
NO3061760T3 (cg-RX-API-DMAC7.html) 2008-09-18 2018-04-07
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
NZ705372A (en) 2012-09-18 2018-07-27 Auspex Pharmaceuticals Inc Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2021128797A (ru) * 2014-02-07 2021-11-26 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение

Also Published As

Publication number Publication date
CY1125058T1 (el) 2023-06-09
CN106456629A (zh) 2017-02-22
MX387625B (es) 2025-03-18
US20210196702A1 (en) 2021-07-01
NZ725826A (en) 2023-05-26
US20200101063A1 (en) 2020-04-02
KR20160147044A (ko) 2016-12-21
EP3936130A1 (en) 2022-01-12
RU2016147523A3 (cg-RX-API-DMAC7.html) 2018-12-28
US20170071932A1 (en) 2017-03-16
IL248745B (en) 2022-07-01
HRP20220025T1 (hr) 2022-04-01
RS65359B1 (sr) 2024-04-30
KR20250029267A (ko) 2025-03-04
KR20220140647A (ko) 2022-10-18
AU2015256012B2 (en) 2020-07-23
IL248745A0 (en) 2017-01-31
RU2016147523A (ru) 2018-06-08
JP2024153782A (ja) 2024-10-29
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
LT3139925T (lt) 2022-01-25
EP4389227A2 (en) 2024-06-26
CA2947736A1 (en) 2015-11-12
SMT202200193T1 (it) 2022-07-21
DK3139925T3 (da) 2021-12-20
SMT202400199T1 (it) 2024-07-09
EP3139925B1 (en) 2021-12-01
SI3936130T1 (sl) 2024-05-31
RS62782B1 (sr) 2022-01-31
PT3936130T (pt) 2024-04-17
KR20200133003A (ko) 2020-11-25
EP3936130B1 (en) 2024-02-14
RU2753740C2 (ru) 2021-08-23
JP2021191799A (ja) 2021-12-16
CN112741836A (zh) 2021-05-04
WO2015171802A1 (en) 2015-11-12
JP2017514850A (ja) 2017-06-08
JP6635945B2 (ja) 2020-01-29
PL3139925T3 (pl) 2022-03-21
JP2019218407A (ja) 2019-12-26
EP3139925A1 (en) 2017-03-15
KR20240011255A (ko) 2024-01-25
CA2947736C (en) 2023-04-18
HUE066361T2 (hu) 2024-07-28
MX2016014429A (es) 2017-04-06
SI3139925T1 (sl) 2022-04-29
HUE057839T2 (hu) 2022-06-28
EP4389227A3 (en) 2024-09-04
ES2976207T3 (es) 2024-07-26
DK3936130T3 (da) 2024-03-25
LT3936130T (lt) 2024-04-25
CN112741835A (zh) 2021-05-04
HRP20240459T1 (hr) 2024-06-21
FI3936130T3 (fi) 2024-04-23
PL3936130T3 (pl) 2024-06-10

Similar Documents

Publication Publication Date Title
IL248745A0 (en) Preparations for the treatment of excessive movement disorders
IL247515A0 (en) Snekribirock for the treatment of leprosy
PT3169328T (pt) Derivados de quinolina para o tratamento de doenças inflamatórias
IL247155A0 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
IL248856A0 (en) New treatment
ZA201700183B (en) Acetylcholinesterase inhibitors for treatment of dermatological conditions
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
PL3164394T3 (pl) Inhibitory GLS1 do leczenia chorób
SG11201609993YA (en) Treatment of immune disorders
IL246721B (en) History of 5-benzylisoquinoline for the treatment of cardiovascular diseases
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
PT3122349T (pt) Composições para o tratamento da autodigestão
GB201416832D0 (en) Methods of treatment
SG11201702700UA (en) Methods for the treatment of peri-implantitis
PL2937084T3 (pl) Sposób leczenia hipercholesterolemii
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201417719D0 (en) New treatment
GB201408384D0 (en) New treatment